2016
DOI: 10.18620/ctt-1866-8836-2016-5-3-51-53
|View full text |Cite
|
Sign up to set email alerts
|

Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-SCT) with Post-Transplant Cyclophosphamide for haematological malignancies: a single centre experience

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 4 publications
0
1
0
Order By: Relevance
“…Unfortunately, this approach led to primary non-engraftment, probably, due to residual recipient cells that promoted the graft rejection. Risks of non-engraftment with standard transplant approaches with haploidentical stem cell source are well known and can be ameliorated with higher number of infused stem cells, more intense conditioning regimens and additional techniques of transplant processing [29,30]. To enable engraftment, the second haploidentical HSCT was performed with more intense conditioning regimen and peripheral blood stem cells as transplant source.…”
Section: Discussionmentioning
confidence: 99%
“…Unfortunately, this approach led to primary non-engraftment, probably, due to residual recipient cells that promoted the graft rejection. Risks of non-engraftment with standard transplant approaches with haploidentical stem cell source are well known and can be ameliorated with higher number of infused stem cells, more intense conditioning regimens and additional techniques of transplant processing [29,30]. To enable engraftment, the second haploidentical HSCT was performed with more intense conditioning regimen and peripheral blood stem cells as transplant source.…”
Section: Discussionmentioning
confidence: 99%